Compared to agents with high SGLT2 selectivity, low SGLT2 selectivity was associated with a significantly lower risk of stroke (HR, 0.63; 95% CI, 0.48–0.81) in patients with eGFR lower than 60 mL/min/1.73 m2, marking a significant difference between the two pharmacological groups (p = 0.047) (Supplementary Fig. 10). Here, SLC5A2 is linked to stroke disorder.